Multidimensional regulatory architecture of endometrial receptivity and its translational implications for...

Endometrial receptivity within the window of implantation (WOI) has been increasingly recognized as an independent determinant of pregnancy outcome in assisted reproduction. Persistent recurrent implantation failure (RIF) is observed in a substantial subset of cycles even after transfer of high-quality embryos, which points toward endometrial factors as targets for closer investigation. Mechanistic work has predominantly been confined to individual signaling pathways examined in isolation, and convergence of hormonal, immune, and epigenetic systems on the receptive state remains insufficiently characterized. Structural readouts dominate at the clinical interface, where endometrial thickness and Doppler indices afford limited insight into molecular dynamics. Consistent clinical benefit has not been delivered by transcriptomic-guided transfer strategies across randomized controlled trials. Evidence is synthesized here across three regulatory tiers of receptivity control. The hormonal signaling network centered on the estrogen and progesterone axis is reviewed together with auxiliary endocrine modulators. The immune regulatory network is dissected through uterine natural killer (uNK) cells, regulatory T (Treg) cells, and macrophage phenotypic transitions. The epigenetic layer is addressed at the level of DNA methylation, histone modification, and non-coding RNA activity. Cross-axis coupling is then examined, with leukemia inhibitory factor (LIF) positioned as a convergence node that integrates endocrine input with immune output and chromatin state. Imaging, molecular profiling, and liquid biopsy are each appraised against current evidence. Translational obstacles imposed by the phenotypic heterogeneity of implantation failure are then considered. Receptivity emerges as a product of coordinated multi-tier regulation rather than as the output of any single pathway. Mechanism-informed stratification, integrating mechanistic evidence with multimodal patient data, lies at the next frontier of clinical translation.